Omeros Corporation (OMER) Given “Buy” Rating at Cantor Fitzgerald
Cantor Fitzgerald reissued their buy rating on shares of Omeros Corporation (NASDAQ:OMER) in a research note released on Monday morning. They currently have a $21.00 target price on the biopharmaceutical company’s stock.
OMER has been the topic of several other reports. Zacks Investment Research lowered Omeros Corporation from a hold rating to a sell rating in a research note on Wednesday, October 12th. FBR & Co reaffirmed an outperform rating and issued a $38.00 price objective on shares of Omeros Corporation in a research note on Wednesday, June 29th. Maxim Group reaffirmed a buy rating and issued a $30.00 price objective on shares of Omeros Corporation in a research note on Thursday, July 28th. Wedbush reiterated an outperform rating and set a $56.00 target price (down from $62.00) on shares of Omeros Corporation in a report on Thursday, August 11th. Finally, S&P Equity Research raised their target price on Omeros Corporation from $7.65 to $8.63 in a report on Monday. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $32.45.
Shares of Omeros Corporation (NASDAQ:OMER) traded down 1.645% on Monday, hitting $7.475. 158,801 shares of the stock traded hands. The firm’s 50 day moving average is $10.51 and its 200-day moving average is $11.63. Omeros Corporation has a 12 month low of $7.26 and a 12 month high of $16.80. The company’s market cap is $293.72 million.
Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.18. The firm earned $10 million during the quarter, compared to analyst estimates of $9.80 million. The business’s revenue for the quarter was up 212.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.44) earnings per share. Equities analysts predict that Omeros Corporation will post ($1.55) earnings per share for the current year.
In other news, VP Marcia S. Kelbon sold 16,000 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $10.91, for a total value of $174,560.00. Following the completion of the sale, the vice president now directly owns 179,597 shares in the company, valued at approximately $1,959,403.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Marcia S. Kelbon sold 15,900 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $11.56, for a total value of $183,804.00. Following the completion of the sale, the vice president now owns 179,497 shares of the company’s stock, valued at $2,074,985.32. The disclosure for this sale can be found here. Company insiders own 13.60% of the company’s stock.
Large investors have recently modified their holdings of the stock. Sheaff Brock Investment Advisors LLC purchased a new stake in shares of Omeros Corporation during the second quarter worth $105,000. Bourgeon Capital Management LLC purchased a new stake in shares of Omeros Corporation during the second quarter worth $158,000. BlackRock Advisors LLC increased its stake in shares of Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 173 shares during the period. Mesirow Financial Investment Management Equity Management purchased a new stake in shares of Omeros Corporation during the second quarter worth $244,000. Finally, Gradient Investments LLC increased its stake in shares of Omeros Corporation by 3.3% in the third quarter. Gradient Investments LLC now owns 25,285 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 814 shares during the period. Institutional investors and hedge funds own 48.04% of the company’s stock.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.